

Stock Data

Share Price:	6.50p
Market Cap:	£10.1m
Shares in issue:	156.1m

Company Profile

Sector:	Pharmaceuticals
Ticker:	N4P
Exchange:	AIM

Activities

N4 Pharma plc ('N4P, 'the Group') is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help the delivery of cancer immunotherapy drugs and improve the delivery of viral vaccines. Nuvec®, the Company's lead development is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments.

1-year Share price performance



Source: LSE

Past performance is not an indication of future performance.

Turner Pope contact details

Turner Pope Investments (TPI) Ltd
8 Frederick's Place
London
EC2R 8AB

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Attention is drawn to the disclaimers and risk warnings at the end of this document.

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

TPI acts as joint broker to N4 Pharma plc

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Barry Gibb
Research Analyst
Tel: 0203 657 0050
barry.gibb@turnerpope.com

Andrew Thacker
Corporate Broking & Sales
Tel: 0203 657 0050
andy.thacker@turnerpope.com

Zoe Alexander
Corporate Broking & Sales
Tel: 0203 657 0050
zoe.alexander@turnerpope.com

N4 Pharma plc

N4P has announced its appointment of [Nanomerics Limited](#) ('Nanomerics') to investigate the potential utility of Nuvec® in cancer therapy. The project is designed to explore the role of its unique, non-viral adjuvant as a delivery system for DNA and small interfering RNA ('siRNA'), with an initial aim to test a silica based, delivery system in a proof of concept ('POC') preclinical tumour model (the 'Oncology Programme'). Not only could this represent a third commercial application for Nuvec® addressing a [giant, unsatisfied and rapidly growing market](#), but also offer potential to be developed as a combination product capable of carrying an external nucleic acid load and an internal small molecule chemotherapeutic. Utilising Nanomerics' advanced technologies, that are designed to address bioavailability challenges across a broad range of drugs, including low molecular weight hydrophobics, peptides, and nucleic acid based products, N4P seeks to demonstrate Nuvec's novel potential to become a delivery system for oncology therapeutics. Taken together with its two existing programmes, feasibility work into oral applications and the ongoing technology transfer for Nuvec's manufacture, the next six months or so is likely to be pivotal for N4P as a greater understanding of its potential becomes more clearly established.

Nanomerics - Utilising its MET platform to improve drug delivery

N4P has been working with Nanomerics since [11 February 2020](#). Its scientists have been developing and evaluating gene delivery systems for over two decades, including the delivery of genes to tumours. It has applied its existing expertise with what it has learnt about Nuvec® in scoping out a two-stage work programme to assess the potential within oncology therapeutics.

The programme is expected to commence immediately and expected to take up to 12 months, running in parallel to the Group's ongoing vaccine delivery work. Stage 1 will focus on the formulation of Nuvec® with a therapeutic DNA plasmid; Stage 2 will see the candidate formulation evaluated *in vivo* in a subcutaneous tumour model to examine tumour regression following multiple local or systemic injections. Nanomerics' approach has been validated through out-licensing deals and collaborations with blue-chip pharmaceutical, nutraceutical and agro-chemical industry partners.

N4P moving into a pivotal six months

The Group's successful [£2m \(gross\) equity placing](#) that was completed in May 2020, along with the [exercising of certain warrants and options](#), sufficiently bolstered its balance sheet to ensure that the development work, which has set a faster pace in the second half, can remain in a 'higher gear' as studies, now including those with Nanomerics, move into their next stages. In expectation of continued relaxation of lockdown restrictions in 2021, TPI considers monthly operational expenses will remain higher than the c.£98k/month seen in H1 2020, as acquired aggregate data sets are utilised in forthcoming *in vivo* studies and the more recently identified opportunity for oral delivery is also progressed. Potentially, the outcome of these findings will be sufficient to attract formal participation in a COVID-19 or other vaccine development programme(s), thereby moving Nuvec® toward its first (partner-dependent) clinical trials collaboration along with demonstration of its GMP scalability.

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as joint broker to N4 Pharma plc ('N4 Pharma') which is listed on the AIM Market of the London Stock Exchange ('AIM'), with effect from Admission of the Placing Shares to trading on AIM.

TPI's private and institutional clients may hold, subscribe for or buy or sell N4 Pharma's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of N4 Pharma.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.